Cargando…
Risk of Developing Melanoma With Systemic Agents Used to Treat Psoriasis: A Review of the Literature
BACKGROUND: Psoriasis is a chronic inflammatory skin disease induced by autoimmune-like dysregulation of the immune system. Treatment options have drastically evolved in recent years, and treatment advances that target specific cytokines and other molecules involved in dysregulation have had a profo...
Autores principales: | Semaka, Amy, Salopek, Thomas G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750137/ https://www.ncbi.nlm.nih.gov/pubmed/34392725 http://dx.doi.org/10.1177/12034754211038509 |
Ejemplares similares
-
Recurrence of Melanoma after Starting Apremilast for Psoriasis
por: Salopek, Thomas G.
Publicado: (2017) -
Rheumatology Image of the Month: A Low Resource Innovation With
Measurable Results
por: Semaka, Amy, et al.
Publicado: (2023) -
Adherence to guidelines in the use of biological agents to treat psoriasis in Brazil
por: Silveira, Miriam Sanches do Nascimento, et al.
Publicado: (2014) -
Risk for Hepatitis B Virus Reactivation in Patients with Psoriasis Treated with Biological Agents: A Systematic Review and Meta-Analysis
por: Wang, Xinyu, et al.
Publicado: (2022) -
Amelanotic Melanoma Concealed by Psoriasis
por: CURMAN, Philip, et al.
Publicado: (2020)